This is a preview of subscription content, log in via an institution to check access.
Notes
Bristol-Myers Squibb provided financial support for the study.
Reference
Juday T, et al. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. ClinicoEconomics and Outcomes Research : 2 Sep 2013. Available from: URL: http://dx.doi.org/10.2147/CEOR.S47486
Rights and permissions
About this article
Cite this article
Is Atripla better value for money in HIV infection?. PharmacoEcon Outcomes News 687, 7 (2013). https://doi.org/10.1007/s40274-013-0722-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0722-x